sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised

Experimental Eye Research

Volumn 88, Issue 5, 2009, Pages 880-888

  Chen, Dongmei ^a   Wei, Yi ^a   Li, Xiaohong ^a   Epstein, Seth ^a   Wolosin, J Mario ^a   Asbell, Penny ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

compromised ocular surface; cytokines; dry eye disease; PGE2; sPLA2 IIa

Indexed keywords

INTERLEUKIN 1BETA; PROSTAGLANDIN E2; SECRETORY PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; DESICCATION; DRY EYE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LACRIMAL FLUID; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CONJUNCTIVA; CYTOKINES; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRY EYE SYNDROMES; EPITHELIAL CELLS; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; SIMIAN VIRUS 40; TEARS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64849116599     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.11.035     Document Type: Article

References (66)

1. Adibhatla R.M., and Hatcher J.F. Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat. Brain. Res. 1134 (2007) 199-205
2. Adibhatla R.M., Dempsy R., and Hatcher J.F. Integration of cytokine biology and lipid metabolism in stroke. Front Biosci. 13 (2008) 1250-1270
3. Aho H.J., Saari K.M., Kallajoki M., and Nevalainen T.J. Synthesis of group II phospholipase A2 and lysozyme in lacrimal glands. Investig. Ophthalmol. Vis. Sci. 37 (1996) 1826-1832
4. Aho V.V., Nevalainen T.J., Paavilainen V., and Saari K.M. Group IIA phospholipase A2 content of tears in patients with keratoconjunctivitis sicca. Graefes Arch. Clin. Exp. Ophthalmol. 240 (2002) 521-523
5. Aho V.V., Holopainen J.M., Tervo T., Moilanen J.A., Nevalainen T., and Saari K.M. Group IIA phospholipase A(2) content in tears of patients having photorefractive keratectomy. J. Cataract. Refract. Surg. 29 (2003) 2163-2167
6. Araki-Sasaki K., Ohashi Y., Sasabe T., Hayashi K., Watanabe H., Tano Y., and Handa H. An SV40-immortalized human corneal epithelial cell line and its characterization. Investig. Ophthalmol. Vis. Sci. 36 (1995) 614-621
7. Atsumi G., Murakami M., Tajima M., Shimbara S., Hara N., and Kudo I. The perturbed membrane of cells undergoing apoptosis is susceptible to type II secretory phospholipase A2 to liberate arachidonic acid. Biochim. Biophys. Acta 1349 (1997) 43-54
8. Bidgood M.J., Jamal O.S., Cunningham A.M., Brooks P.M., and Scott K.F. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J. Immunol. 165 (2000) 2790-2797
9. Birts C.N., Barton C.H., and Wilton D.C. A catalytically independent physiological function for human acute phase protein group IIA phospholipase A2: cellular uptake facilitates cell debris removal. J. Biol. Chem. 283 (2008) 5034-5045
10. Boilard E., Bourgoin S.G., Bernatchez C., Poubelle P.E., and Surette M.E. Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB J. 17 (2003) 1068-1080
11. Boilard E., Bourgoin S.G., Bernatchez C., and Surette M.E. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 102 (2003) 2901-2909
12. Bomalaski J.S., Lawton P., and Browning J.L. Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. J. Immunol. 146 (1991) 3904-3910
13. Bowton D.L., Seeds M.C., Fasano M.B., Goldsmith B., and Bass D.A. Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. Am. J. Respir. Crit. Care Med. 155 (1997) 421-425
14. Bradley J.D., Dmitrienko A.A., Kivitz A.J., Gluck O.S., Weaver A.L., Wiesenhutter C., Myers S.L., and Sides G.D. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32 (2005) 417-423
15. Brasnu E., Brignole-Baudouin F., Riancho L., Warnet J.M., and Baudouin C. Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines. Mol. Vis. 14 (2008) 394-402
16. Buckland A.G., and Wilton D.C. The antibacterial properties of secreted phospholipases A(2). Biochim. Biophys. Acta 1488 (2000) 71-82
17. Cai T.Q., Thieblemont N., Wong B., Thieringer R., Kennedy B.P., and Wright S.D. Enhancement of leukocyte response to lipopolysaccharide by secretory group IIA phospholipase A2. J. Leukoc. Biol. 65 (1999) 750-756
18. Cirino G., Cicala C., Sorrentino L., Maiello F.M., and Browning J.L. Recombinant secreted nonpancreatic phospholipase A2 induces a synovitis-like inflammation in the rat air pouch. J. Rheumatol. 21 (1994) 824-829
19. Coleman R.A., Smith W.L., and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46 (1994) 205-229
20. Dennis E.A. Diversity of group types, regulation, and function of phospholipase A2. J. Biol. Chem. 6 (1994) 13057-13060
21. Diebold Y., Calonge M., Enriquez de Salamanca A., Callejo S., Corrales R.M., Saez V., Siemasko K.F., and Stern M.E. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Investig. Ophthalmol. Vis. Sci. 44 (2003) 4263-4274
22. Fijneman R.J., and Cormier R.T. The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. Front Biosci. 13 (2008) 4144-4174
23. Girgis D.O., Dajcs J.J., and O'Callaghan R.J. Phospholipase A2 activity in normal and Staphylococcus aureus-infected rabbit eyes. Investig. Ophthalmol. Vis. Sci. 44 (2003) 197-202
24. Glasson M., Stapleton F., and Willcox M. Lipid, lipase and lipocalin differences between tolerant and intolerant contact lens wearers. Curr. Eye Res. 25 (2002) 227-235
25. Gluud B.S., Jensen O.L., Krogh E., and Birgens H.S. Prostaglandin E2 level in tears during postoperative inflammation of the eye. Acta Ophthalmol. (Copenh.) 63 (1985) 375-379
26. Hara S., Kudo I., Chang H.W., Matsuta K., Miyamoto T., and Inoue K. Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis. J. Biochem. 105 (1989) 395-399
27. Jaulmes A., Thierry S., Janvier B., Raymondjean M., and Marechal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J. 20 (2006) 1727-1729
28. Kari O., Aho V.V., Peltonen S., Saari J.M., Kari M., Maatta M., Collan Y., and Saari K.M. Group IIA phospholipase A(2) concentration of tears in patients with ocular rosacea. Acta Ophthalmol. Scand. 83 (2005) 483-486
29. Khan A.H., Carson R.J., and Nelson S.M. Prostaglandins in labor - a translational approach. Front Biosci. 13 (2008) 5794-5809
30. Lambeau G., and Gelb M.H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu. Rev. Biochem. 77 (2008) 495-520
31. Lambeau G., and Lazdunski M. Receptors for a growing family of secreted phospholipases A2. Trends. Pharmacol. Sci. 20 (1999) 162-170
32. Lavappa K.S. Survey of ATCC stocks of human cell lines for HeLa contamination. In Vitro 14 (1978) 469-475
33. Lilja I., Smedh K., Olaison G., Sjodahl R., Tagesson C., and Gustafson-Svard C. Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis. Gut 37 (1995) 380-385
34. Lin M.K., Farewell V., Vadas P., Bookman A.A., Keystone E.C., and Pruzanski W. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J. Rheumatol. 23 (1996) 1162-1166
35. Luo L., Li D.Q., Doshi A., Farley W., Corrales R.M., and Pflugfelder S.C. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Investig. Ophthalmol. Vis. Sci. 45 (2004) 4293-4301
36. Marsh P., and Pflugfelder S.C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106 (1999) 811-816
37. Matsuo T. Trehalose protects corneal epithelial cells from death by drying. Br. J. Ophthalmol. 85 (2001) 610-612
38. Mayer R.J., and Marshall L.A. New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J. 7 (1993) 339-348
39. Menschikowski M., Hagelgans A., and Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat. 79 (2006) 1-33
40. Menschikowski M., Hagelgans A., Gussakovsky E., Kostka H., Paley E.L., and Siegert G. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia 10 (2008) 279-286
41. Minami T., Tojo H., Shinomura Y., Matsuzawa Y., and Okamoto M. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 35 (1994) 1593-1598
42. Murakami M., Kuwata H., Amakasu Y., Shimbara S., Nakatani Y., Atsumi G., and Kudo I. Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J. Biol. Chem. 272 (1997) 19891-19897
43. Nevalainen T.J., Aho H.J., and Peuravuori H. Secretion of group 2 phospholipase A2 by lacrimal glands. Investig. Ophthalmol. Vis. Sci. 35 (1994) 417-421
44. Nevalainen T.J., Graham G.G., and Scott K.F. Antibacterial actions of secreted phospholipases A2. Review. Biochim. Biophys. Acta 1781 (2008) 1-9
45. Osiri M., and Moreland L.W. Specific cyclooxygenase 2 inhibitors: a new choice of nonsteroidal anti-inflammatory drug therapy. Arthritis Care Res. 12 (1999) 351-362
46. Peuravuori H., Kari O., Peltonen S., Aho V.V., Saari J.M., Collan Y., Maatta M., and Saari K.M. Group IIA phospholipase A2 content of tears in patients with atopic blepharoconjunctivitis. Graefes Arch. Clin. Exp. Ophthalmol. 242 (2004) 986-989
47. Pflugfelder S.C., Tseng S.C., Pepose J.S., Fletcher M.A., Klimas N., and Feuer W. Epstein-Barr virus infection and immunologic dysfunction in patients with aqueous tear deficiency. Ophthalmology 97 (1990) 313-323
48. Praml C., Savelyeva L., Le Paslier D., Siracusa L.D., Buchberg A.M., Schwab M., and Amler L.C. Human homologue of a candidate for the Mom1 locus, the secretory type II phospholipase A2 (PLA2S-II), maps to 1p35-36.1/D1S199. Cancer Res. 55 (1995) 5504-5506
49. Pruzanski W., Scott K., Smith G., Rajkovic I., Stefanski E., and Vadas P. Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids. Inflammation 16 (1992) 451-457
50. Pruzanski W., Albin-Cook K., Laxer R.M., MacMillan J., Stefanski E., Vadas P., and Silverman E.D. Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity. J. Rheumatol. 21 (1994) 1951-1954
51. Qu X.D., and Lehrer R.I. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect Immun. 66 (1998) 2791-2797
52. Ramoner R., Putz T., Gander H., Rahm A., Bartsch G., Schaber C., and Thurnher M. Dendritic-cell activation by secretory phospholipase A2. Blood 105 (2005) 3583-3587
53. Ravaux L., Denoyelle C., Monne C., Limon I., Raymondjean M., and El Hadri K. Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPAR-beta and the proto-oncogene BCL-6. Mol. Cell Biol. 27 (2007) 8374-8387
54. Reid R.C. Inhibitors of secretory phospholipase A2 group IIA. Curr. Med. Chem. 12 (2005) 3011-3026
55. Reynolds I.J. 1,5-(Diethylamino)piperidine, a novel spermidine analogue that more specifically activates the N-methyl-d-aspartate receptor-associated polyamine site. Mol. Pharmacol. 41 (1992) 989-992
56. Saari K.M., Aho V., Paavilainen V., and Nevalainen T.J. Group II PLA(2) content of tears in normal subjects. Investig. Ophthalmol. Vis. Sci. 42 (2001) 318-320
57. Saegusa J., Akakura N., Wu C.Y., Hoogland C., Ma Z., Lam K.S., Liu F.T., Takada Y.K., and Takada Y. Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J. Biol. Chem. 283 (2008) 26107-26115
58. Solomon A., Rosenblatt M., Monroy D., Ji Z., Pflugfelder S.C., and Tseng S.C. Suppression of interleukin 1alpha and interleukin 1beta in human limbal epithelial cells cultured on the amniotic membrane stromal matrix. Br. J. Ophthalmol. 85 (2001) 444-449
59. Song C.H., Choi J.S., Kim D.K., and Kim J.C. Enhanced secretory group II PLA2 activity in the tears of chronic blepharitis patients. Investig. Ophthalmol. Vis. Sci. 40 (1999) 2744-2748
60. Song X.J., Li D.Q., Farley W., Luo L.H., Heuckeroth R.O., Milbrandt J., and Pflugfelder S.C. Neurturin-deficient mice develop dry eye and keratoconjunctivitis sicca. Investig. Ophthalmol. Vis. Sci. 44 (2003) 4223-4229
61. Stefanski E., Pruzanski W., Sternby B., and Vadas P. Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis. J. Biochem. 100 (1986) 1297-1303
62. Styles L.A., Schalkwijk C.G., Aarsman A.J., Vichinsky E.P., Lubin B.H., and Kuypers F.A. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 87 (1996) 2573-2578
63. Touqui L., and Alaoui-El-Azher M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 1 (2001) 739-754
64. Turner H.C., Budak M.T., Akinci M.A., and Wolosin J.M. Comparative analysis of human conjunctival and corneal epithelial gene expression with oligonucleotide microarrays. Investig. Ophthalmol. Vis. Sci. 48 (2007) 2050-2061
65. Wilson H.A., Allred D.V., O'Neill K., and Bell J.D. Activities and interactions among phospholipases A2 during thapsigargin-induced S49 cell death. Apoptosis 5 (2000) 389-396
66. Wu Y.Z., Medjane S., Chabot S., Kubrusly F.S., Raw I., Chignard M., and Touqui L. Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappaB. Am. J. Respir. Crit. Care Med. 168 (2003) 692-699